Article Text

Download PDFPDF
Difference between drospirenone-containing oral contraceptives and other oral contraceptives related to risk of venous thromboembolism
  1. Marcel Leppée, PhD, MD1,
  2. Josip Culig, PhD, MD2
  1. Health Information Manager, Department of Pharmacoepidemiology, Andrija Stampar Institute of Public Health, Zagreb, Croatia; marcel.leppee@stampar.hr
  2. Associate Professor, Department of Pharmacoepidemiology, Andrija Stampar Institute of Public Health, Zagreb, Croatia; josip.culig@stampar.hr

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We wish to comment on the Dinger and Shapiro commentary article published in the January 2012 issue of this Journal.1

Following the publication of papers regarding the risk of venous thromboembolism (VTE) with combined oral contraceptives (COCs) we would like to share some information regarding comparison between drospirenone-containing COCs and other COCs in Croatia. This short study was conducted during the 3-year period 2008–2010 using data on drug utilisation and data on side effects from the Agency for Medicinal Products and Medical Devices of Croatia (HALMED). The total female population aged 15–49 years was about 1 050 000. Like other COCs in Croatia, drospirenone/ethinylestradiol (DRSP/EE) is issued on private prescription in pharmacies. They are usually prescribed by gynaecologists, but may also be prescribed by other specialists. The DRSP-containing COC, Yasmin®, …

View Full Text

Footnotes

  • Competing interests None.